Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Setmelanotide
Other

Setmelanotide

Tracked across 1 events · 6 articles · First seen May 01, 2026 · Last active May 04, 2026

Sentiment
70
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the NewsDesk Dashboard
Events (1)
6 70
Business
IMCIVREE EU Approval, Positive Data
Rhythm Pharmaceuticals announced that the International — European Commission has expanded the marketing authorization for Setmelanotide (setmelanotide) to treat acquired hypothalamic obesity in adults and children aged 4 years and older. This authorization follows the…
Impact: Setmelanotide (setmelanotide) received expanded marketing authorization from the International — European Commission for acquired hypothalamic obesity, and its long-term efficacy data was presented, indicating significant potential for Rhythm Pharmaceuticals.
May 01, 2026 · 6 articles
NEWSDESK
Track Setmelanotide live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.